Global pharmaceutical companies increase investment in China's biotech sector

After this year's „two sessions“, representatives of the world's leading pharmaceutical companies visited Beijing to explore new opportunities. Biomedicine was identified for the first time as a new pillar industry, linked to China's accelerated efforts to build a „Healthy China“ initiative by 2035.

Significant investments, including Eli Lilly's $3 billion plan and AstraZeneca's commitment of approximately $14 billion, underscore the strong attractiveness of the Chinese market for global drugmakers.

CMG